Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Amgen

Revenues up 12% in the quarter to $6.4 billion.

By: Contract Pharma

Contract Pharma Staff

Amgen

3Q Revenues: $6.4 billion (+12%)

3Q Earnings: $2.0 billion (+3%)

YTD Revenues: $18.8 billion (+9%)

YTD Earnings: $5.6 billion (-8%)

Comments: Product sales increased 12% globally, driven by 18% volume growth across a number of our newer products, including Otezla, MVASI, KANJINTI, and Repatha, partially offset by declines in select products from the impact of COVID-19, and biosimilar and generic competition. Prolia sales increased 11% to $701 million. EVENITY generated $59 million of sales in the quarter. Repatha sales increased 22% to $205 million. Aimovig sales increased 59% to $105 million. Parsabiv sales increased 17% to $183 million. Otezla generated $538 million of sales in the quarter. Enbrel sales decreased 3% to $1.3 billion. AMGEVITA increased 31% to $80 million. KYPROLIS sales decreased 2% to $260 million. XGEVA sales increased 1% to $481 million. Vectibix sales declined 2% to $193 million. Nplate sales increased 9% to $212 million. BLINCYTO sales increased 5% to $89 million. MVASI generated $231 million of sales in the quarter. KANJINTI generated $167 million of sales in the quarter. Neulasta sales decreased 22% to $555 million due to increased biosimilar competition. EPOGEN sales decreased 31% to $149 million. Aranesp sales decreased 15% to $384 million driven by lower net selling price and competition. Sensipar/Mimpara sales decreased 64% to $39 million due to generic competition.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters